Chemotherapy and intraoperative radiation therapy for operable stage III non-small cell lung cancer.
The study was undertaken to evaluate results of combined modality treatment including intraoperative radiation therapy (IORT) in 202 patients with stage III non-small cell lung cancer. The 5-year disease-free and overall survival rates in patients who underwent 15 Gy IORT were 18. 7% and 29. 2%, respectively. The overall response rate to preoperative chemotherapy with paclitaxel/carboplatin was 43. 7%, treatment was well tolerated. Preoperative chemotherapy with paclitaxel/ carboplatin in combination with 15 Gy IORT led to a significant increase in the 5-year disease-free and overall survival rates to 31. 4% and 39. 2%, respectively (p<0. 05). The 5-year disease-free and overall survival rates were respectively 32. 6% and 40. 8% in patients who received additional administration of cisplatin combined with 10 Gy IORT. Radiosensibilization with cisplatin in patients treated with 15 Gy IORT increased the 5-year disease-free and overall survival rates to 41. 7% and 47. 9%, respectively (p<0. 05).